Zolbetuximab Is a Promising Therapy for HER2-Negative Gastric Cancer
XTalks
JULY 17, 2023
Consequently, new therapies are continuously investigated to increase and prolong survival rates. This investigational first-in-class Claudin 18.2 Phase III Clinical Trials Underpinning the Applications The applications are grounded on two Phase III clinical trials, SPOTLIGHT and GLOW. percent compared to CAPOX alone.
Let's personalize your content